Neoplasms

• EMA approval · 2026-08-25
  EMA Authorised: Akynzeo (netupitant;palonosetron hydrochloride) — Helsinn Birex Pharmaceuticals Ltd

  The EMA authorised Akynzeo (netupitant and palonosetron hydrochloride) for vomiting, nausea, cancer-related indications.

• EMA approval · 2026-08-06
  EMA Authorised: Thiotepa Riemser (thiotepa) — Esteve Pharmaceuticals GmbH

  The EMA has authorised Thiotepa Riemser (thiotepa) for hematopoietic stem cell transplantation and neoplasms, with Esteve Pharmaceuticals Gm…

• EMA approval · 2023-10-23
  EMA Authorised: Thiotepa Riemser (thiotepa) — Esteve Pharmaceuticals GmbH

  EMA authorised Thiotepa Riemser for indications related to hematopoietic stem cell transplantation and neoplasms.

• EMA approval · 2022-05-24
  EMA Authorised: Amifampridine SERB (amifampridine phosphate) — SERB SA

  European Medicines Agency authorises amifampridine phosphate (SERB) for various neuromuscular and autoimmune conditions, with Lambert-Eaton …

• CLINICAL_TRIALS approval · 2014-01-17
  Clinical Trial Update: Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

  The update indicates Voraxaze (glucarpidase) has received marketing approval to treat methotrexate toxicity in cancer patients.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.